Differential CD40/CD40L expression results in counteracting antitumor immune responses

Journal of Immunology

Volumn 178, Issue 4, 2007, Pages 2047-2055

  Murugaiyan, Gopal ^a   Agrawal, Reena ^a   Mishra, Gyan C ^a   Mitra, Debashis ^a   Saha, Bhaskar ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; INTERLEUKIN 10; INTERLEUKIN 4; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS LINKING; CYTOKINE PRODUCTION; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MEMORY T LYMPHOCYTE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION;

EID: 33846904768     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.4.2047     Document Type: Article

References (39)

1. Bromley, S. K., W. R. Burack, K. G. Johnson, K. Somersalo, T. N. Sims, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin. 2001. The immunological synapse. Annu. Rev. Immunol. 19: 375-396.
2. Germain, R. N., and I. Stefanova. 1999. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu. Rev. Immunol. 17: 467-522.
3. Chambers, C. A., M. S. Kuhns, J. G. Egen, and J. P. Allison. 2001. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19: 565-594.
4. Salomon, B., and J. A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19: 225-252.
5. Dutton, R. W., L. M. Bradley, and S. L. Swain. 1998. T cell memory. Annu. Rev. Immunol. 16: 201-223.
6. Najafian, N., and S. J. Khoury. 2003. T cell costimulatory pathways: blockade for autoimmunity. Expert Opin. Biol. Ther. 3: 227-236.
7. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22: 329-360.
8. Houghton, A. N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180: 1-4.
9. Houghton, A. N., J. S. Gold, and N. E. Blachere. 2001. Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13: 134-140.
10. Alexandroff, A. B., A. M. Jackson, T. Paterson, H. L. Haley, J. A. Ross, D. L. Longo, W. J. Murphy, K. James, and D. D. Taub. 2000. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol. Immunol. 37: 515-526.
11. Diehl, L., A. T. den Boer, S. P. Schoenberger, E. I. van der Voort, T. N. Schumacher, C. J. Melief, R. Offringa, and R. E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5: 774-779.
12. Stumbles, P. A., R. Himbeck, J. A. Frelinger, E. J. Collins, R. A. Lake, and B. W. Robinson. 2004. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J. Immunol. 173: 5923-5928.
13. Chiodoni, C., P. Paglia, A. Stoppacciaro, M. Rodolfo, M. Parenza, and M. P. Colombo. 1999. Dendritic cells infiltrating tumors cotransduced with granulo-cyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J. Exp. Med. 190: 125-133.
14. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
15. Valenzuela, J., C. Schmidt, and M. Mescher. 2002. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J. Immunol. 169: 6842-6849.
16. Curtsinger, J. M., D. C. Lins, and M. F. Mescher. 2003. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 197: 1141-1151.
17. + T cells in melanoma patients receiving IL-12. Cancer Res. 60: 3559-3568.
18. + leukocytes and Fas/FasL interactions to induce apoptosis following IL-12 gene therapy in a metastatic model of prostate cancer. Hum. Gene Ther. 12: 1485-1498.
19. Hanks, B. A., J. Jiang, R. A. Singh, W. Song, M. Barry, M. H. Huls, K. M. Slawin, and D. M. Spencer. 2005. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat. Med. 11: 130-137.
20. Quezada, S. A., L. Z. Jarvinen, E. F. Lind, and R. J. Noelle. 2004. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22: 307-328.
21. Walker, S., R. Redlinger, Jr., and E. M. Barksdale, Jr. 2005. Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression. J. Pediatr. Surg. 40: 244-249.
22. French, L. E., B. Huard, M. Wysocka, R. Shane, E. Contassot, J. F. Arrighi, V. Piguet, S. Calderara, and A. H. Rook. 2005. Impaired CD40L signaling is a cause of defective IL-12 and TNF-α production in Sezary syndrome: circumvention by hexameric soluble CD40L. Blood 105: 219-225.
23. Shurin, M. R., Z. R. Yurkovetsky, I. L. Tourkova, L. Balkir, and G. V. Shurin. 2002. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int. J. Cancer 101: 61-68.
24. Baley, P. A., K. Yoshida, W. Qian, I. Sehgal, and T. C. Thompson. 1995. Progression to androgen insensttivity in a novel in vitro mouse model for prostate cancer. J. Steroid Biochem. Mol. Biol. 52: 403-413.
25. Ahuja, S. S. 2001. In vitro generation of functional human and murine DCs. Methods Mol. Biol. 156: 67-77.
26. Kelsall, B. L., E. Stuber, M. Neurath, and W. Strober. 1996. Interleukin-12 production by DCs: the role of CD40-CD40L interactions in Th1 T-cell responses. Ann. NY Acad. Sci. 795: 116-126.
27. Matzinger, P. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145: 185-192.
28. Mathur, R. K., A. Awasthi, P. Wadhone, B. Ramanamurthy, and B. Saha. 2004. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. [Published erratum appears in 2004 Nat. Med. 10: 755.] Nat. Med. 10: 540-544.
29. Bhushan, A., and L. R. Covey. 2001. CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes. Immunol. Res. 24: 311-324.
30. Vissers, J. L., B. C. van Esch, G. A. Hofman, M. L. Kapsenberg, F. R. Weller, and A. J. van Oosterhout. 2004. Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model. J. Allergy Clin. Immunol. 113: 1204-1210.
31. Pellat-Deceunynck, C., M. Amiot, N. Robillard, J. Wijdenes, and R. Bataille. 1996. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res. 56: 1909-1916.
32. Funakoshi, S., D. L. Longo, M. Beckwith, D. K. Conley, G. Tsarfaty, I. Tsarfaty, R. J. Armitage, W. C. Fanslow, M. K. Spriggs, and W. J. Murphy. 1994. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83: 2787-2794.
33. - tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. USA 99: 5561-5566.
34. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184: 747-752.
35. Mackey, M. F., R. J. Barth, Jr., and R. J. Noelle. 1998. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J. Leukocyte Biol. 63: 418-428.
36. + T cells in vivo. J. Immunol. 163: 2561-2567.
37. + T cells that expands in patients receiving interleukin-12. J. Clin. Invest. 102: 561-575.
38. Urosevic, M., and R. Dummer. 2003. HLA-G and IL-10 expression in human cancer: different stories with the same message. Semin. Cancer Biol. 13: 337-342.
39. + T helper cells. J. Exp. Med. 196: 255-260.